Search results for:
epoprostenol
epoprostenol
- Restricted Veletri (IV) --> restricted to pulmonology/medical-intensivist, cardiology, rheumatology, and pediatric critical care
- Restricted Miscellaneous
- Non-formulary
Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
Flolan |
POWDER FOR INJECTION, INTRAVENOUS |
0.5 mg, 1.5 mg |
|
|
|
|
Veletri |
POWDER FOR INJECTION, INTRAVENOUS |
0.5 mg, 1.5 mg |
|
|
|
|
Last updated: Nov. 30, 2022
Intravenous epoprostenol may be administered through inhalation utilizing the approved PowerPlan.
VELETRI for IV injection is classified as formulary status, restricted to pulmonology/medical-intensivist, cardiology, rheumatology, and pediatric critical care. Stock as needed.
VELETRI for Inhalation is classified as formulary status, restricted to pulmonology/medical-intensivists, cardiothoracic surgeons, anesthesiologists, trauma surgeons, and cardiologist.
***Inhaled epoprostenol is dosed on ideal body weight rounded to the nearest 5 kg***
Ideal body weight calculation:
Inhaled VELETRI tip sheet, Inhaled VELETRI dosing guideline
FLOLAN is classified as non-formulary, not stocked. Flolan is automatically interchanged to VELETRI.
Veletri is available through two specialty pharmacies:
Ordering Veletri -- Enrollment form must be completed and signed by a prescriber
Reviewed: April 27, 2005 (FLOLAN) and 26 May 2015 (Veletri/Flolan), Jan 2021 (Intravenous epoprostenol)
Updated: November 2022 (inhalation)